Copy/Paste the key inputs from the product brochure, per guidance from Marketing.

The axial spondyloarthritis (AxSpA) market boasts biologics representing two distinct drug classes, the blockbuster tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen’s Enbrel, AbbVie’s Humira, Janssen’s Remicade and Simponi / Simponi Aria, and UCB’s Cimzia) and two IL-17 inhibitors (Novartis’s Cosentyx and Eli Lilly’s Taltz). The TNF-α inhibitors are the most widely prescribed biologics in AxSpA patients refractory to nonsteroidal anti-inflammatory drugs (NSAIDs). However, these agents face a competitive threat, both from the launch of cost-effective biosimilars and the growing IL-17 class, which has efficacy data that have met more-stringent clinical trial endpoints. Cimzia was approved by the FDA in 2019 for nonradiographic (nr)-AxSpA, marking the first FDA approval for that subpopulation, followed by Cosentyx and Taltz in June 2020. The impending entry of additional IL-17 inhibitors (UCB’s bimekizumab and Kyowa Hakko Kirin’s Lumicef) and the first oral targeted therapies—Jak inhibitors—for this indication (Pfizer’s Xeljanz and AbbVie's Rinvoq) will also shift market dynamics.

Questions answered:

  • How large is the treatable AxSpA population, and how will diagnosis / drug-treatment rates change over time?
  • What are interviewed experts’ insights on current treatment options for ankylosing spondylitis (AS) and nr-AxSpA? What clinical needs remain unfulfilled?
  • What pipeline products are the most promising, and what sales / uptake could they secure in AxSpA? What therapies of note are progressing in earlier phases?
  • What are the drivers and constraints in the AxSpA market, and how will the market evolve over the forecast period?

Content highlights:

Geographies: United States, EU5, Japan

Primary Research: ~30 country-specific interviews with thought-leading rheumatologists; Supported by survey data collected for this and other DRG research

Epidemiology: Diagnosed prevalent cases of axial spondyloarthritis by country, ankylosing spondylitis and nonradiographic axial spondyloarthritis subpopulations

Forecast: 10-year, annualized, drug-level sales and patient share of key axial spondyloarthritis therapies through 2029, segmented by brands/generics and epidemiological subpopulations

Emerging therapies: Phase III: 4 drugs; Phase II: 1 drugs

Product description:

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Axial Spondyloarthritis - Landscape & Forecast - Disease Landscape & Forecast
    • COVID-19
      • Key Findings
        • Key Updates
          • Q1 2021
            • March 2021
            • February 2021
            • January 2021
          • Q4 2020
            • December 2020
          • Q3 2020
            • September 2020
          • Q2 2020
            • May 2020
        • Market Outlook
          • Key Findings
            • Market Share of Drug Classes for Axial Spondyloarthritis: 2019
            • Market Share of Drug Classes for Axial Spondyloarthritis: 2029
            • Axial Spondyloarthritis SWOT Analysis
          • COVID-19: Areas of Potential Forecast Impact
            • Market Drivers and Constraints
              • What Factors Are Driving the Market for Axial Spondyloarthritis?
              • What Factors Are Constraining the Market for Axial Spondyloarthritis?
            • Drug-Class Specific Trends
              • Major-Market Sales of NSAIDs for Axial Spondyloarthritis by Drug Class
              • Major-Market Sales of TNF-Alpha Inhibitors for Axial Spondyloarthritis
              • Major-Market Sales of Branded and Biosimilar TNF-Alpha Inhibitors
              • Sales of TNF-Alpha Inhibitors for Axial Spondyloarthritis by Market Segment
              • Major-Market Sales of IL-17 Inhibitors for Axial Spondyloarthritis
              • Sales of IL-17 Inhibitors for Axial Spondyloarthritis by Market Segment
              • Sales of Jak Inhibitors for Axial Spondyloarthritis by Market Segment
          • Forecast
            • Market Forecast Assumptions - Axial Spondyloarthritis (2019-2029) - January 2021
            • Market Forecast Dashboards - Axial Spondyloarthritis (2019-2029) - January 2021
          • Etiology and Pathophysiology
            • Disease Overview
              • Classification Criteria in Axial Spondyloarthritis
                • Systems Used to Classify Axial Spondyloarthritis
              • Presentation and Disease Progression
                • Key Pathways and Drug Targets
                  • Pathways Involved in Inflammation and Bone Damage in Axial Spondyloarthritis
              • Epidemiology
                • Key Findings
                  • Epidemiology Populations
                    • Disease Definition
                    • Methods
                    • Sources Used for Total Prevalent Cases of Axial Spondyloarthritis
                    • Number of Total Prevalent Cases of Axial Spondyloarthritis in the Major Pharmaceutical Markets: 2019-2029 (Thousands)
                    • Disease Definition
                    • Methods
                    • Sources Used for Total Prevalence of Ankylosing Spondylitis
                    • Total Prevalent Cases of Ankylosing Spondylitis in the Major Pharmaceutical Markets: 2019-2029 (Thousands)
                    • Disease Definition
                    • Methods
                    • Sources Used for Total Prevalent Cases of Nonradiographic Axial Spondyloarthritis
                    • Total Prevalent Cases of Nonradiographic Axial Spondyloarthritis in the Major Pharmaceutical Markets: 2019-2029 (Thousands)
                    • Disease Definition
                    • Methods
                    • Sources Used for Total Prevalent Cases of Non-Radiographic Axial Spondyloarthritis
                    • HLA-B27 Positive Cases in the Major Pharmaceutical Markets: 2019-2029 (Thousands)
                    • Diagnosed Prevalent Cases of Axial Spondyloarthritis (Thousands)
                    • Drug-Treated Prevalent Cases of Axial Spondyloarthritis (Thousands)
                • Current Treatment
                  • Key Findings
                    • Treatment Goals
                      • Key Endpoints Used in Clinical Trials for Axial Spondyloarthritis
                    • Key Current Therapies
                      • Overview
                      • Mechanism of Action of Key Current Drug Classes Used for Axial Spondyloarthritis
                      • Current Treatments Used for Axial Spondyloarthritis
                      • Market Events Impacting the Use of Key Current Therapies for Axial Spondyloarthritis
                      • Advantages and Disadvantages of NSAIDs
                      • Expert Insight: NSAIDs
                      • Advantages and Disadvantages of Conventional DMARDs
                      • Expert Insight: Conventional DMARDs
                      • Advantages and Disadvantages of Adalimumab
                      • Expert Insight: Adalimumab
                      • Advantages and Disadvantages of Etanercept
                      • Expert Insight: Etanercept
                      • Advantages and Disadvantages of Infliximab
                      • Expert Insight: Infliximab
                      • Advantages and Disadvantages of Simponi
                      • Expert Insight: Simponi
                      • Advantages and Disadvantages of Cimzia
                      • Expert Insight: Cimzia
                      • Advantages and Disadvantages of Cosentyx
                      • Ongoing Clinical Development of Cosentyx
                      • Key Ongoing Clinical Trials of Cosentyx in the Treatment of Axial Spondyloarthritis
                      • Expert Insight: Cosentyx
                      • Taltz
                      • Advantages and Disadvantages of Taltz
                      • Expert Insight: Taltz
                    • Medical Practice
                      • Overview
                      • Country-Specific Axial Spondyloarthritis Treatment Guidelines
                      • Factors Influencing Drug Selection in Axial Spondyloarthritis
                      • Treatment Decision Tree for Axial Spondyloarthritis: United States
                      • Treatment Decision Tree for Axial Spondyloarthritis: Europe
                      • Treatment Decision Tree for Axial Spondyloarthritis: Japan
                  • Unmet Need Overview
                    • Current and Future Attainment of Unmet Needs in Axial Spondyloarthritis
                    • Top Unmet Needs in Axial Spondyloarthritis: Current and Future Attainment
                    • Expert Insight: Unmet Need in Axial Spondyloarthritis
                  • Emerging Therapies
                    • Key Findings
                      • Pipeline Trends in Axial Spondyloarthritis
                    • Key Emerging Therapies
                      • Key Therapies in Development for Axial Spondyloarthritis
                      • Estimated Launch Dates of Key Emerging Therapies for the Treatment of Axial Spondyloarthritis
                      • Bimekizumab Profile
                      • Key Ongoing Clinical Trials of Bimekizumab in the Treatment of AxSpA
                      • Analysis of the Clinical Development Program for Bimekizumab
                      • Expert Insight: Bimekizumab
                      • Expectations for Launch and Sales Opportunity of Bimekizumab in Axial Spondyloarthritis
                      • Lumicef Profile
                      • Analysis of the Clinical Development Program for Lumicef
                      • Expert Insight: Lumicef
                      • Expectations for Launch and Sales Opportunity of Lumicef in Axial Spondyloarthritis
                      • Key Development Milestones for Lumicef in the Treatment of Axial Spondyloarthritis
                      • Xeljanz Profile
                      • Analysis of the Clinical Development Program for Xeljanz
                      • Expert Insight: Xeljanz
                      • Expectations for Launch and Sales Opportunity of Xeljanz in Axial Spondyloarthritis
                      • Rinvoq Profile
                      • Key Ongoing Clinical Trials of Rinvoq in the Treatment of AxSpA
                      • Analysis of the Clinical Development Program for Rinvoq
                      • Expert Insight: Rinvoq
                      • Expectations for Launch and Sales Opportunity of Rinvoq in Axial Spondyloarthritis
                      • Filgotinib Profile
                      • Key Ongoing Clinical Trials of Filgotinib in the Treatment of AxSpA
                      • Analysis of the Clinical Development Program for Filgotinib
                      • Expert Insight: Filgotinib
                      • Expectations for Launch and Sales Opportunity of Filgotinib in Axial Spondyloarthritis
                    • Early-Phase Pipeline Analysis
                      • Select Compounds in Phase II Development for Axial Spondyloarthritis
                  • Access & Reimbursement Overview
                    • Region-Specific Reimbursement Practices
                      • Key Market Access Considerations in Axial Spondyloarthritis: United States
                      • General Reimbursement Environment: United States
                      • Key Market Access Considerations in Axial Spondyloarthritis: EU5
                      • General Reimbursement Environment: EU5
                      • Key Market Access Considerations in Axial Spondyloarthritis: Japan
                      • General Reimbursement Environment: Japan
                  • Appendix
                    • Key Abbreviations Related to Axial Spondyloarthritis
                    • Brands, Marketers, and Generic Availability of Key Therapies for Axial Spondyloarthritis by Market
                    • Axial Spondyloarthritis Bibliography

                Author(s): Swati Kinger, M.B.A.; Mudasir Khan, M.P.H.

                Swati Kinger, M.B.A., is an associate analyst on the Immune and Inflammatory Disorders team at DRG, part of Clarivate. Prior to joining DRG, she was an associate consultant for a life sciences firm, where she worked on syndicated offerings and ad-hoc requests involving patient journeys, market assessment, and competitive intelligence. She holds a bachelor’s degree in pharmacy and an M.B.A. in pharmacy from the National Institute of Pharmaceutical Education and Research in India.

                Mudasir Khan, M.P.H., is a senior epidemiologist at DRG, part of Clarivate. He received his M.P.H. from the Tata Institute of Social Sciences in Mumbai.


                Related Reports

                Axial Spondyloarthritis - Access & Reimbursement - Detailed, Expanded Analysis: Axial Spondyloarthritis (ankylosing Spondylitis And Nonradiographic Axial Spondyloarthritis) - US

                The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: the tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen’s Enbrel, AbbVie’s...

                View Details

                Axial Spondyloarthritis - Unmet Need - Detailed, Expanded Analysis: Ankylosing Spondylitis (US & EU)

                In the last 15 years, TNF-α inhibitors (AbbVie’s Humira, Amgen / Pfizer’s Enbrel, Janssen’s Remicade and Simponi, UCB’s Cimz...

                View Details

                Axial Spondyloarthritis - Current Treatment - Detailed, Expanded Analysis : Treatment Algorithms : Claims Data Analysis : Ankylosing Spondylitis (US)

                MARKET OUTLOOKAnkylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and the axi...

                View Details